Synendos Therapeutics AG’s Post

Cellular models of neurodegenerative diseases play an integral role in preclinical drug discovery, and safety studies. Patient iPSC-derived dopamine neurons along with Multi-Electrode Array (MEA) assay provide a useful platform to investigate functional phenotypes both at the individual neuron and network levels. CRL now offers testing of small molecules aimed at reversing pathophysiology linked with cellular models of neurodegenerative diseases. For more details contact our client service https://lnkd.in/eGbNJsNC or connect with our specialists Amit Kumar Chouhan, PhD, Eddie Burns and Dario Magnani #CharlesRiver #drugdevelopment #Pharmacology #neuroscience #drugdiscovery #neurology #neurodegeneration #parkinsonsdisease Follow us at Discovery | Charles River

The generation and accumulation of α-Synuclein amyloid fibrils in the brain is a major pathological hallmark of Parkinsons´s disease. Accordingly, inhibition of fibril generation could be a viable treatment strategy. In this AppNote potential inhibitors of α-Synuclein fibrilization were evaluated using a Thioflavin T-based approach. BMG LABTECH´s Omega series reader provided the perfect measurement platform for both, primary nucleation and elongation assays, as they are the gold standard for extended shaking assays. #applicationnote #microplatereaders #platereader #neuroscience #drugdevelopment #pharmacology #wearebmglabtech #laboratorywork #laboratoryequipment parkinsonsdisease

Is the pathogenesis of Parkinson’s disease rooted in early neurodevelopmental defects? Congratulations to Isabel Rosety, Alise Žagare, Jens Schwamborn, and their team, for the important paper using patient-specific midbrain #organoids carrying a heterozygous GBA-N370S mutation in the GBA1gene to explore the pathophysiology of Parkinson’s disease and suggest the potential for new therapeutic approaches. Visit our website to learn more and discover how the team used Axion’s #MaestroMEA platform to perform complex electrophysiological experiments on the 3D organoids with no labels, dyes, or complicated steps. 📝https://bit.ly/4bqlv63 #neuroscience #stemcells #parkinsonsresearch #biotech

Just Published: Our new Lab Note on performing Calcium Flux assays with our new iCell Sensory Neurons. Let me know if you want to discuss how our iCell Sensory Neurons can help your pain research

We are excited to invite you to an upcoming webinar focused on the post-operative translational model. In this webinar, we will explore the challenges in developing new post-surgical pain agents, the use of preclinical animal models for surgical pain, and a success story of translating the pig post-operative pain model to the clinic. Register here today: https://hubs.la/Q02HF-Hm0 #drugdevelopment #translationalresearch #painresearch #neuroscience #preclinicalresearch

A novel engineered assembloid platform may help accelerate therapeutic discovery for Parkinson’s disease (PD). Congratulations to Alp Ozgun, David Lomboni, Fabio Variola, and their team, for the important paper 📝 describing the development of a novel engineered assembloid platform to recapitulate key attributes of PD dysfunction in vitro. Visit our website to learn more and discover how the researchers used Axion’s next-generation Maestro Pro MEA platform to explore the dysfunctional dopaminergic network associated with PD in real time with no labels, dyes, or complicated steps.  🔗 https://bit.ly/3PGneLr #parkinsonsdiseaseresearch #iPSCs #neuroscience

Elucidating the underlying molecular alterations in Alzheimer’s Disease (AD) pathology is essential for understanding disease mechanisms and developing effective therapeutic interventions. Multiplexed imaging techniques such as MERFISH have emerged as powerful tools for comprehensive molecular and cellular profiling at single-cell resolution. Download our poster presented by Dr. Bin Wang, PhD at SFN 2023 to learn how we used MERSCOPE Protein CO-detection to study the spatial distribution of biomarkers and cellular heterogeneity of a normal aging human brain sample and a human AD brain sample: https://lnkd.in/etzgf5NF #SFN23 #Vizgen #MERSCOPE #MERFISH #SpatialTranscriptomics #SpatialGenomics #Neuroscience #BrainScience #CellAtlas #AlzheimersDisease #SpatialData #DataAnalysis #ProteinCoDetection #SpatialMultiomics

At EphyX Neuroscience we focus on in vitro electrophysiology for preclinical research and drug discovery in the Central Nervous System (CNS) area. Our mission is to empower our clients with the knowledge they need to make informed decisions about their compound selection by providing comprehensive insights into the mechanisms of action and neuronal physiology, using both rodent and human preparations. We understand that every research project is unique, which is why we offer customized solutions tailored to consider your specific needs and constraints. Whether you're looking to optimize your lead compound selection, understand the mechanism of action of a new drug, or investigate the physiological properties of neuronal networks, we have the expertise and technology to help you achieve your goals. #Electrophysiology #DrugDiscovery #CNSResearch #DrugDevelopment #PreclinicalResearch #ResearchAndDevelopment #Neurophysiology #CentralNervousSystem #Neuroscience #CRO #Pharma #ContractResearch

#alhumdulillah I'm thrilled to announce the publication of our manuscript, "Autophagy-associated non-coding RNAs: Unraveling their impact on Parkinson's disease pathogenesis," in CNS Neuroscience & Therapeutics (Impact Factor: 5.5). This study explores the critical role of non-coding RNAs in regulating autophagy processes, offering new insights into their potential as therapeutic targets for Parkinson's disease. Our findings highlight the complex interplay between these RNAs and the pathogenesis of Parkinson's, opening avenues for novel treatment strategies. A great thanks to all the co-authors (Professors) Mahamedha D., sachin singh, Kamal Dua, Vetriselvan Subramaniyan, Ph.D., FMSA., Access the full manuscript here: https://lnkd.in/gGDgy5p5 #Neuroscience #ParkinsonsDisease #Autophagy #NonCodingRNAs #Research #OpenAccess #CNSNeuroscienceTherapeutics

At Delix Therapeutics, we are leading a new paradigm in CNS treatments, advancing #neuroplastogens, compounds that quickly and durably promote neuroplasticity to help repair atrophied neurons.  While neuroplasticity is seen in more traditional antidepressant treatment options like talk therapy, serotonin reuptake inhibitors (SSRIs), or transcranial magnetic stimulation (TMS), our compounds restore neurons in key areas of the brain in a fraction of the time and with a greater magnitude of response. Instead of weeks or months, plasticity is seen in hours or days.  Our innovative approach ensures rapid results, with the goal of delivering effective at-home treatments with improved tolerability and safety. Learn more about our science here: https://lnkd.in/eCRnJMv5   #neuroscience #biotech